![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Clinical data from its AURORA Phase 3 trial will be highlighted in a late-breaking oral presentation during the National Kidney Foundation 2020 Spring Clinical Meetings.
Lead Product(s): Voclosporin,Mycophenolic Acid,Corticosteroids
Therapeutic Area: Nephrology Product Name: Lupkynis
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Otsuka Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2020